|
시장보고서
상품코드
2102155
간신증후군 치료 시장 규모, 점유율, 성장 분석 : 치료법별, 약물 계열별, 질환별, 투여 경로별, 유통 채널별, 최종사용자별, 지역별 - 업계 예측(2026-2033년)Hepatorenal Syndrome Treatment Market Size, Share, and Growth Analysis, By Treatment Type, By Drug Class, By Disease Type, By Route of Administration, By Distribution Channel, By End User, By Region - Industry Forecast 2026-2033 |
||||||
세계의 간신증후군(HRS) 치료 시장 규모는 2024년에 3억 1,240만 달러로 평가되었으며, 2025년 3억 3,052만 달러에서 2033년까지 5억 1,890만 달러로 확대되어 예측 기간(2026-2033년) 동안 CAGR 5.8%로 성장할 것으로 전망됩니다.
간신증후군(HRS) 치료 세계 시장은 진행성 간 질환으로 인한 신부전을 대상으로 하는 의약품, 생물학적 제제 및 지지요법을 포괄합니다. HRS에 수반되는 높은 사망률로 인해 효과적인 치료법에 대한 시급한 필요성이 대두되고 있으며, 시장은 기존의 혈관수축제에서 특히 텔리프레신-알부민 요법과 같은 혁신적인 병용요법으로 전환되고 있습니다. 이러한 변화는 임상시험의 성공을 바탕으로 연구 개발(R&D) 투자 증가와 표준화된 병원 프로토콜 도입을 촉진하고 있습니다. 선택적 혈관수축제와 결합된 알부민 기반 치료법의 사용 확대는 HRS의 근본적인 혈역학적 불균형을 해결하는 것으로, 이러한 치료법에 대한 수요 증가로 이어지고 있습니다. 또한, AI는 치료법 개발에 혁명을 일으키고 있으며, 환자 계층화를 가속화하고 맞춤형 의료를 강화함으로써 치료 선택의 폭을 넓히고, 시장 상황을 호전시키며, 시장 성장의 모멘텀을 창출하고 있습니다.
세계 간신증후군 치료 시장의 성장요인
만성 간질환 유병률의 증가로 인해 간신증후군 치료가 필요한 환자층이 대폭 확대되고 있으며, 의료 서비스 제공자들은 효과적인 치료법을 모색해야 하는 상황에 직면해 있습니다. 진행된 간 기능 장애를 보이는 환자가 늘어남에 따라 신장 합병증 발생률도 상승하고 있으며, 그 결과 전문적인 치료법에 대한 수요가 지속적으로 증가하고 있습니다. 이러한 임상적 수요의 증가로 인해 제약사들은 연구 개발에 주력할 수밖에 없으며, 이는 궁극적으로 시장 내 제품의 다양화에 기여하고 있습니다. 또한, 이 질환이 주는 부담에 대한 인식이 높아지면서 처방 행위가 촉진되고, 혁신적인 치료 솔루션에 대한 투자가 뒷받침됨에 따라 시장의 성장과 확대가 더욱 가속화되고 있습니다.
세계 간신증후군 치료 시장의 제약요인
세계 간신증후군 치료 시장은 보험 급여 범위의 제한으로 인해 큰 제약을 받고 있으며, 이는 고가의 치료법에 대한 환자의 접근을 방해하고 있습니다. 보험사가 엄격한 적격 기준을 설정하거나 최소한의 보상률만 제시하는 경우, 의료 종사자들은 이러한 고가의 치료법을 처방하는 데 소극적인 태도를 보이며, 보다 보수적인 관리 방식에 의존하는 경우가 빈번합니다. 이러한 재정적 과제는 치료 수용률을 저하시킬 뿐만 아니라, 제약사가 시장에서 입지를 확대하기 위해 막대한 자원을 투입하는 것을 주저하게 만드는 요인이 되고 있습니다. 그 결과, 시장 성장이 저해되고 있으며, 가격 압박과 환급에 대한 불확실성이 혁신적인 치료법의 광범위한 채택을 방해하고, 치료 환경 전반의 발전을 제약하고 있습니다.
세계 간신증후군 치료 시장 동향
세계 간신증후군 치료 시장에서는 정밀 의학의 통합을 향한 뚜렷한 동향이 나타나고 있으며, 치료 접근 방식이 근본적으로 변화하고 있습니다. 임상의들은 개별 환자의 필요에 맞춘 치료를 제공하기 위해 유전체 프로파일링 및 바이오마커 기반 전략을 점점 더 많이 활용하고 있으며, 이를 통해 효능을 높이고 부작용을 최소화하고 있습니다. 이러한 변화에 따라 제약사들은 치료제 개발과 병행하여 동반진단제 개발에도 주력하고 있습니다. 그 결과, 생명공학 기업과 진단제 제조사 간의 제휴가 점점 더 보편화되고 있으며, 전 세계 다양한 의료 시스템에서 가치 기반의 성과를 추구하는 지불 주체의 기대에 부응하는 맞춤형 치료 모델이 실현되고 있습니다.
자주 묻는 질문
목차
소개
조사 방법
주요 요약
시장 역학과 전망
주요 시장 인사이트
세계의 간신증후군 치료 시장 규모 : 치료 유형별
세계의 간신증후군 치료 시장 규모 : 약물 계열별
세계의 간신증후군 치료 시장 규모 : 질환 유형별
세계의 간신증후군 치료 시장 규모 : 투여 경로별
세계의 간신증후군 치료 시장 규모 : 유통 채널별
세계의 간신증후군 치료 시장 규모 : 최종사용자별
세계의 간신증후군 치료 시장 규모 : 지역별
경쟁 정보
주요 기업 개요
결론과 제안
KSM 26.08.03Global Hepatorenal Syndrome Treatment Market size was valued at USD 312.4 Million in 2024 and is poised to grow from USD 330.52 Million in 2025 to USD 518.9 Million by 2033, growing at a CAGR of 5.8% during the forecast period (2026-2033).
The global market for hepatorenal syndrome (HRS) treatment encompasses pharmaceuticals, biologics, and supportive care aimed at renal failure resulting from advanced liver disease. High mortality rates associated with HRS create an urgent need for effective therapies, transitioning the market from traditional vasoconstrictor agents to innovative combination treatments, notably the terlipressin-albumin regimen. This shift has catalyzed increased R&D investment and the adoption of standardized hospital protocols based on clinical trial success. The growing use of albumin-based therapies combined with selective vasoconstrictors addresses the fundamental hemodynamic imbalances behind HRS, leading to heightened demand for these treatments. Additionally, AI is revolutionizing therapy development, enabling faster patient stratification and enhancing personalized care, thus widening the therapeutic landscape and creating momentum for market growth.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Hepatorenal Syndrome Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Hepatorenal Syndrome Treatment Market Segments Analysis
Global hepatorenal syndrome treatment market is segmented by treatment type, drug class, disease type, route of administration, distribution channel, end user and region. Based on treatment type, the market is segmented into Vasoconstrictor Therapy, Albumin Therapy, Combination Therapy (Vasoconstrictors + Albumin), Renal Replacement Therapy (Dialysis), Liver Transplantation and Others. Based on drug class, the market is segmented into Vasopressin Analogues, Alpha-Adrenergic Agonists, Somatostatin Analogues, Plasma Volume Expanders (Albumin) and Others. Based on disease type, the market is segmented into Type 1 Hepatorenal Syndrome (HRS-AKI) and Type 2 Hepatorenal Syndrome (HRS-CKD/Non-AKI). Based on route of administration, the market is segmented into Intravenous, Subcutaneous and Oral. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies and Online Pharmacies. Based on end user, the market is segmented into Hospitals, Specialty Clinics, Ambulatory Surgical Centers and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Driver of the Global Hepatorenal Syndrome Treatment Market
The increasing incidence of chronic liver disease is significantly broadening the population in need of hepatorenal syndrome treatments, driving healthcare providers to pursue effective therapeutic options. As more patients experience advanced liver dysfunction, the occurrence of renal complications rises, resulting in a continuous demand for specialized interventions. This growing clinical need compels pharmaceutical companies to focus on research and development, ultimately contributing to a more diverse range of products in the market. Additionally, the rising awareness of the disease burden stimulates prescribing practices and boosts investments in innovative treatment solutions, further propelling market growth and expansion.
Restraints in the Global Hepatorenal Syndrome Treatment Market
The Global Hepatorenal Syndrome Treatment market faces significant restrictions due to limited reimbursement coverage policies, which hinder patient access to costly therapies. When insurance providers implement stringent eligibility criteria or offer minimal reimbursement rates, healthcare professionals are often reluctant to prescribe these expensive treatments, frequently resorting to more conservative management approaches. This financial challenge not only decreases treatment uptake but also discourages manufacturers from committing substantial resources to expand their presence in the market. As a result, market growth is stifled, with pricing pressures and reimbursement uncertainties hampering the broader adoption of innovative therapeutic options and constraining the development of the overall treatment landscape.
Market Trends of the Global Hepatorenal Syndrome Treatment Market
The Global Hepatorenal Syndrome Treatment market is witnessing a significant trend towards the integration of precision medicine, fundamentally transforming therapeutic approaches. Clinicians are increasingly employing genomic profiling and biomarker-driven strategies to tailor treatments to individual patient needs, enhancing efficacy and minimizing side effects. This shift is encouraging pharmaceutical companies to focus on developing companion diagnostics alongside their therapeutic offerings. As a result, collaborations between biotech firms and diagnostic companies are becoming more prevalent, leading to a personalized care model that meets the demands of evolving payer expectations for value-based outcomes across diverse healthcare systems globally.
Table of Contents
Introduction
- Objectives of the Study
- Market Definition & Scope
Research Methodology
- Research Process
- Secondary & Primary Data Methods
- Market Size Estimation Methods
Executive Summary
- Global Market Outlook
- Key Market Highlights
- Segmental Overview
- Competition Overview
Market Dynamics & Outlook
- Macro-Economic Indicators
- Drivers & Opportunities
- Restraints & Challenges
- Supply Side Trends
- Demand Side Trends
- Porters Analysis & Impact
- Competitive Rivalry
- Threat of Substitute
- Bargaining Power of Buyers
- Threat of New Entrants
- Bargaining Power of Suppliers
Key Market Insights
- Key Success Factors
- Market Impacting Factors
- Top Investment Pockets
- Ecosystem Mapping
- Market Attractiveness Index 2025
- PESTEL Analysis
- Regulatory Landscape
Global Hepatorenal Syndrome Treatment Market Size by Treatment Type & CAGR (2026-2033)
- Market Overview
- Vasoconstrictor Therapy
- Albumin Therapy
- Combination Therapy (Vasoconstrictors + Albumin)
- Renal Replacement Therapy (Dialysis)
- Liver Transplantation
- Others
Global Hepatorenal Syndrome Treatment Market Size by Drug Class & CAGR (2026-2033)
- Market Overview
- Vasopressin Analogues
- Alpha-Adrenergic Agonists
- Somatostatin Analogues
- Plasma Volume Expanders (Albumin)
- Others
Global Hepatorenal Syndrome Treatment Market Size by Disease Type & CAGR (2026-2033)
- Market Overview
- Type 1 Hepatorenal Syndrome (HRS-AKI)
- Type 2 Hepatorenal Syndrome (HRS-CKD/Non-AKI)
Global Hepatorenal Syndrome Treatment Market Size by Route of Administration & CAGR (2026-2033)
- Market Overview
- Intravenous
- Subcutaneous
- Oral
Global Hepatorenal Syndrome Treatment Market Size by Distribution Channel & CAGR (2026-2033)
- Market Overview
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Global Hepatorenal Syndrome Treatment Market Size by End User & CAGR (2026-2033)
- Market Overview
- Hospitals
- Specialty Clinics
- Ambulatory Surgical Centers
- Others
Global Hepatorenal Syndrome Treatment Market Size & CAGR (2026-2033)
- North America (Treatment Type, Drug Class, Disease Type, Route of Administration, Distribution Channel, End User)
- US
- Canada
- Europe (Treatment Type, Drug Class, Disease Type, Route of Administration, Distribution Channel, End User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
- Asia Pacific (Treatment Type, Drug Class, Disease Type, Route of Administration, Distribution Channel, End User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
- Latin America (Treatment Type, Drug Class, Disease Type, Route of Administration, Distribution Channel, End User)
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa (Treatment Type, Drug Class, Disease Type, Route of Administration, Distribution Channel, End User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa
Competitive Intelligence
- Top 5 Player Comparison
- Market Positioning of Key Players, 2025
- Strategies Adopted by Key Market Players
- Recent Developments in the Market
- Company Market Share Analysis, 2025
- Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)
Key Company Profiles
- Mallinckrodt plc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Grifols SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Orphan Therapeutics LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Takeda Pharmaceutical Company Limited
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Sanofi SA
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Pfizer Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Novartis AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Baxter International Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- CSL Behring LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Octapharma AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Kedrion Biopharma
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biotest AG
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- LFB USA Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Bio Product Laboratory Ltd
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- China Biologic Products Holdings Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Ferring Pharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Biopas Laboratories
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Cumberland Pharmaceuticals Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Melinta Therapeutics LLC
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
- Salix Pharmaceuticals Inc
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
